ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome.

By Christophe Ginestier, M. Hur, E. Charafe-Jauffret, F. Monville, J. Dutcher, Marty Brown, J. Jacquemier, P. Viens, C. Kleer, Suling Liu and 5 more. Cell Stem Cell, 2007

4,041 citations recorded by the source corpus.

Subfields: Molecular Biology, Oncology, Psychiatry and Mental health

View Paper: https://www.semanticscholar.org/paper/9cdc02577218461dd8b447b2457a9e1cc6c659bf

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Molecular Biology

In Oncology

In Psychiatry and Mental health

Citations in the corpus

ALDH1-positive cancer stem cells mediate metastasis and poor clinical outcome in inflammatory breast cancer (2009, methodology): “This percentage of ALDH1 expression in this patient population is similar to that found in non-IBC (22).”
The molecular mechanisms and therapeutic strategies of EMT in tumor progression and metastasis (2022, background): “Since then, this feature has been found in many CSC subpopulations and other studies have reported that high intracellular ALDH1 activity is a marker of stemness [246, 247].”
Cancer stem cells: current status and evolving complexities. (2012, background): “Furthermore, the ALDHhi and CD44hiCD24lo CSC-enriched subsets in breast cancer bear little overlap within the same tumor (Ginestier et al., 2007).”
Breast cancer stem cells are regulated by mesenchymal stem cells through cytokine networks (2011, methodology): “In addition to the established cell lines, MC1 primary xenografts were developed and used as previously described (16).”
Identification, molecular characterization, clinical prognosis, and therapeutic targeting of human bladder tumor-initiating cells (2009, background): “Candidate T-ICs have been isolated in a variety of solid tumors, including breast (6, 7), brain (8), colorectal (9–11), head and neck (12), pancreatic (13), prostate (14), and melanoma (15), based primarily on the expression of CD44, CD133, ALDH, and ABCB5.”
Breast Cancer Stem Cells Transition between Epithelial and Mesenchymal States Reflective of their Normal Counterparts (2013, methodology): “Furthermore, in primary breast xenografts, CD24 CD44+ and ALDH identified overlapping, but nonidentical cell populations, each capable of initiating tumors in NOD/SCID mice (Ginestier et al., 2007).”
Breast cancer cell lines contain functional cancer stem cells with metastatic capacity and a distinct molecular signature (2009, positive): “Fat pads were prepared as described (15).”
Early dissemination seeds metastasis in breast cancer (2016, positive): “Consistent with previous reports on HER2-stimulated stemness 19,20 Balb-NeuT-derived samples generated significantly higher numbers of spheres than controls (Figure 2b).”
Tumour-initiating cells: challenges and opportunities for anticancer drug discovery (2009, background): “It is also possible to enrich for tumour-initiating cells by selecting other surrogate functional properties of stem cells, such as aldehyde dehydrogenase activit”
MicroRNA miR-34 Inhibits Human Pancreatic Cancer Tumor-Initiating Cells (2009, neutral): “CSCs are a small subpopulation of cells capable of self-renewal and differentiation and have been identified in a variety of tumors [29,32,33,34,35].”
Stem cell and epithelial-mesenchymal transition markers are frequently overexpressed in circulating tumor cells of metastatic breast cancer patients (2009, background): “More recently, ALDH1 was found to be a specific marker for breast cancer stem cells [28].”
Aldehyde Dehydrogenase 1 Is a Tumor Stem Cell-Associated Marker in Lung Cancer (2009, methodology): “Murine and human hematopoietic and neural stem cells have high ALDH activity (10-15).”
Detection, clinical relevance and specific biological properties of disseminating tumour cells (2008, background): “and new ones such as aldehyde dehydrogenase 1 (ALDH1, also known as ALDH1A1”
Mechanisms of chemoresistance in cancer stem cells (2013, methodology): “demonstrated that on average 8% of normal mammary epithelial cells had ALDH activity as measured by ALDEFLUOR-positive staining [41].”
Transient Low Doses of DNA Demethylating Agents Exert Durable Anti-tumor Effects on Hematological and Epithelial Tumor Cells (2012, methodology): “…capacity and stem-like cell activity (Figure 4A) (McDermott andWicha, 2010; Korkaya et al., 2009; Charafe-Jauffret et al., 2009; Dontu et al., 2003; Ginestier et al., 2007; (C) gH2AX foci formation in CD34+ and CD34 Kasumi-1 cells after 72 hr DAC trea calculated as fold change relative to that of…”
Cancer stem cells in solid tumours: accumulating evidence and unresolved questions (2008, background): “In breast carcinomas, high aldehyde dehydrogenase 1 (ALDH1, also known as ALDH1A1 ) activity was recently shown to identify the tumorigenic fractio”